effects of glp-1 receptor agonists on neurological complications of diabetes An analysis the role glucagon-like peptide-1 in cognitive and mental health disorders Diabetic neuropathy: cutting-edge research and

Prospective ultrasound studies show a higher prevalence of residual gastric content in GLP-1 RA users, particularly during dose escalation or when GI symptoms are present

These treatments can be life-changing for overall health, but their success can also bring surprising

Novo Nordisk is putting down up to US$362m to tap into Ascendis TransCon technology for treatments in metabolic and cardiovascular diseases

Metabolic Benefits: Along with weight loss, it has shown promising results in treating Type 2 diabetes, with some studies showing hemoglobin A1c reductions

Can I Take Semaglutide GLP-1 If I Am Not Diabetic?

Compared with SGLT-2 inhibitor use, GLP-1 receptor agonist use was not associated with an increased risk of pulmonary aspiration (pooled risk ratio 0.98, 95% CI 0.73 to 1.31), although it was associated with a higher risk for discontinuation of endoscopy (1.99, 1.56 to 2.53)